These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 2951438

  • 1. Development of host-dependent high-grade tumor-specific immunity through a novel mechanism triggered by the Lyt-2+ tumor-specific T cell clone (K7L) that induces temporal growth of L1210 leukemia-K7L-variant.
    Nagase F, Ueda K, Kawashima K, Jamshedur Rahman SM, Isobe K, Yoshida T, Hasegawa Y, Ando K, Iwamoto T, Nagura E.
    J Immunol; 1987 Apr 01; 138(7):2359-65. PubMed ID: 2951438
    [Abstract] [Full Text] [Related]

  • 2. Induction of high-grade tumor-specific immunity in a host using a cytotoxic T-lymphocyte clone specific for a stable tumor antigen on murine leukemia L1210.
    Rahman SM, Kawashima K, Nakashima I, Nagase F.
    Cancer Res; 1988 Nov 15; 48(22):6450-4. PubMed ID: 3263189
    [Abstract] [Full Text] [Related]

  • 3. Dynamics of generation of antigen loss variants from L1210 murine leukemia clones detected by a tumor-specific T-cell clone.
    Nagase F, Rahman SM, Yokochi T, Kawashima K, Isobe K, Yoshida T, Nagura E, Nakashima I.
    Cancer Res; 1987 Dec 15; 47(24 Pt 1):6494-9. PubMed ID: 3499976
    [Abstract] [Full Text] [Related]

  • 4. Establishment of a murine leukemia L1210-specific T-cell clone displaying novel in vivo anti-tumor activity.
    Nagase F, Ueda K, Nakashima I, Kawashima K, Isobe K, Nagura E, Yamada K, Yokochi T, Hasegawa Y, Yoshida T.
    Int J Cancer; 1986 Dec 15; 38(6):907-14. PubMed ID: 3491792
    [Abstract] [Full Text] [Related]

  • 5. Acceleration of allogeneic antitumor immunity with immune RNA in vitro and T-cell suppression by L1210 tumor bearer spleen cells.
    Miura T, Maekawa T, Kurashige S, Mitsuhashi S.
    Cancer Res; 1981 Feb 15; 41(2):383-98. PubMed ID: 6160907
    [Abstract] [Full Text] [Related]

  • 6. Involvement of cytotoxic T-lymphocytes in the antitumor activity of spergualin against L1210 cells.
    Umezawa H, Nishikawa K, Shibasaki C, Takahashi K, Nakamura T, Takeuchi T.
    Cancer Res; 1987 Jun 15; 47(12):3062-5. PubMed ID: 3495325
    [Abstract] [Full Text] [Related]

  • 7. Clonal variation in tumorigenicity of L1210 lymphoma cells: nontumorigenic variants with an enhanced expression of tumor-associated antigen and Ia antigens.
    Fuji H, Iribe H.
    Cancer Res; 1986 Nov 15; 46(11):5541-7. PubMed ID: 3489524
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
    Fujiwara H, Fukuzawa M, Yoshioka T, Nakajima H, Hamaoka T.
    J Immunol; 1984 Sep 15; 133(3):1671-6. PubMed ID: 6205091
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Rejection of an IA+ variant line of FBL-3 leukemia by cytotoxic T lymphocytes with CD4+ and CD4-CD8- T cell receptor-alpha beta phenotypes generated in CD8-depleted C57BL/6 mice.
    Yoshimura A, Shiku H, Nakayama E.
    J Immunol; 1993 Jun 01; 150(11):4900-10. PubMed ID: 8496592
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Immunobiological characterization of murine LB leukemia and the LBC cell line].
    Hajos SE, Mongini C, Waldner C, Sánchez Lockhart M, Gravisaco MJ, Roig I, Fernańdez T, Alvarez E.
    Medicina (B Aires); 1996 Jun 01; 56 Suppl 1():45-56. PubMed ID: 9224974
    [Abstract] [Full Text] [Related]

  • 18. Cellular basis of immunologic interactions in adoptive T cell therapy of established metastases from a syngeneic murine sarcoma.
    Ward BA, Shu S, Chou T, Perry-Lalley D, Chang AE.
    J Immunol; 1988 Aug 01; 141(3):1047-53. PubMed ID: 3260908
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.